Unusual cutaneous toxicity following treatment with dactinomycin: a report of two cases.
Dactinomycin-induced cutaneous toxicity is rare in pediatric patients not receiving radiation therapy. We describe dactinomycin-related lesions in the axilla, groin, and central line exit site of two children treated for rhabdomyosarcoma, neither of whom had received radiation treatment. One patient was initially treated with systemic antifungal therapy, and developed recurrent lesions on reexposure to the drug. The other was noted to have mild, diffuse hyperpigmentation. Skin biopsies revealed interface dermatitis with syringometaplasia in both cases. Both children recovered uneventfully within 4 weeks. Recognition of unusual rashes with a characteristic distribution in patients receiving dactinomycin should aid in diagnosis, and help avoid unnecessary therapeutic procedures.
Kanwar
V S
VS
Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, TN 38101-0318.
Gajjar
A
A
Ribeiro
R C
RC
Bowman
L
L
Parham
D M
DM
Jenkins
J J
JJ
D002648:Child; D002675:Child, Preschool; D003609:Dactinomycin / Q000009:adverse effects* / Q000627:therapeutic use; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D006801:Humans; D008297:Male; D018232:Rhabdomyosarcoma, Alveolar / Q000188:drug therapy*
D003609:Dactinomycin